当归补血汤与阿托伐他汀通过活化IGF1/IGF1R通路降低动脉粥样硬化斑块易损性

Danggui-Buxue-Tang and Atorvastatin Reduced Atherosclerotic Plaque Vulnerability Through Activating IGF1/IGF1R Pathway

为了探索当归补血汤(DBT)的抗动脉粥样硬化作用机制并比较其与阿托伐他汀抗动脉硬化作用的异同,利用高脂高胆固醇饮食饲喂ApoE-/-雄鼠(16周)模仿动脉粥样硬化易损斑块模型,分别给与DBT和立普妥干预8周,检测动脉粥样硬化进展相关指标.结果表明,DBT与立普妥均能降低血脂,减少巨噬细胞表型,抑制炎症因子和MMPs表达并促进细胞增殖,从而逆转动脉粥样硬化进展,减轻斑块负荷、降低斑块易损性,两给药组组间比较无统计学差异.结论是DBT有不弱于他汀类药物的抗动脉粥样硬化作用,可能的机制是通过上调IGF1表达并活化IGF1/IGF1R通路实现.

In order to explore the anti-atherosclerosis mechanism of Danggui-Buxue-Tang Decoction(DBT)and compare the similarities and differences with the anti-arteriosclerosis effects of atorvastatin,ApoE-/-males(16-week old)were imitated the atherosclerotic vulnerable plaque model and were received DBT and Lipitor intervention for 8 weeks to detect the relevant indicators of atherosclerosis progression.Results showed that both DBT and Lipitor reduced blood lipid,reduced macrophage phenotype,suppressed inflammation,reduced ECM degradation and promoted cell proliferation,thus reversing atherosclerosis progression,reducing plaque load and reducing plaque vulnerability.There was no statistical difference between the two treatment groups.In conclusion,DBT plays an anti-atherosclerotic effect as well as statins do.The possible mechanism is through upregulation of IGF1 expression and activation of the IGF1/IGF1R pathway.